TRIAL DETAIL

Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma

Drug:
Trial Name:
Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma
NCT#:
Conditions:
Sarcoma
Status:
Suspended
Phase:
1
Start Date 07/01/2012
Age of Trial (yrs) 12.4
Treatment Phase:
Gleevec-resistant
Drug Category:
Immune stimulate
Strategy:
Stimulate the immune system
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
20110462
Sponsor:
Edward Ziga, MD, MPH Pediatric Hematology-Oncology - University of Miiami
Patient Contact:
Breelyn Wilky, MD b.wilky@med.miami.edu Emil Kamar e.kamar@med.miami.edu
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Purpose
The use of adjuvant vaccination with autologous dendritic cells (DC) matured in situ after being loaded with tumor lysates derived from autologous refractory sarcoma tissue will be safe, feasible and potentially beneficial for patients diagnosed with sarcoma. This vaccination will result in evidence of immune stimulation against tumor antigens. In addition, combining myeloid derived supressor cells (MDSC) inhibition using gemcitabine with DC vaccination in this method will be safe and feasible and show improved immune parameters over DC vaccination without MDSC inhibition.

Trial Links
 

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
1475 Northwest 12th Ave
Miami
FL
33136
USA